When you dig deeper, many of these patients describe relying solely on the medication without making dietary or exercise changes
You start by taking their quiz or questionnaire, which will collect some basic information about you and your goals, and it will more or less pre-qualify you for treatment
We will then determine the number of patients on GLP-1RA therapy in each group and compare the outcomes
During week one, the most common experience is a noticeable reduction in appetite that feels almost surreal
GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are generally well-tolerated, but like all medications, they can cause side effects
In December 2014, the Food and Drug Administration (FDA) approved liraglutide for weight loss, and semaglutide was approved for diabetes in 2017 and obesity in 2021, opening a new era of obesity treatment